Clinical trials: Airway Control
Chronic Obstructive Pulmonary Disease
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
The purpose of this study is to evaluate the efficacy, safety and tolerability of aclidinium bromide doses compared with placebo in the treatment of moderate to severe, stable chronic obstructive pulmonary disease.
- Trial name
- LAS-MD-38 (NCT01045161)
- Testing
- Aclidinium bromide
- Where
- 112 sites in United States, Canada
- Volunteers
- 544 people
- Sponsor
- AstraZeneca
Uncontrolled Asthma
A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma
A 52-Week, Multicentre, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled…
- Trial name
- STRATOS1 (NCT02161757)
- Testing
- Tralokinumab
- Where
- 243 sites in United States, Argentina and 13 more
- Volunteers
- 1,207 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.
This study will evaluate the efficacy and safety data of AZD8871 in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT03645434
- Testing
- AZD8871, Anoro® Ellipta®
- Where
- 5 sites in Germany, United Kingdom
- Volunteers
- 73 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
This exploratory study will compare the efficacy of the fixed-dose combination (FDC) of aclidinium bromide and formoterol fumarate once daily in the morning and placebo once in the evening vs.
- Trial name
- NCT00706914
- Testing
- Once-daily aclidinium/formoterol, Twice-daily formoterol fumarate, Once-daily formoterol fumarate
- Where
- 40 sites in United States
- Volunteers
- 156 people
- Sponsor
- AstraZeneca
Asthma, Airway Obstruction
Single-dose Crossover Study to Investigate Pharmacodynamics of AZD3199
The purpose of this study is to investigate the pharmacodynamics of single doses of AZD3199 in asthmatic patients.
- Trial name
- NCT00736489
- Testing
- AZD3199, Formoterol
- Where
- 4 sites in Denmark, Sweden
- Volunteers
- 37 people
- Sponsor
- AstraZeneca
Asthma
Early Airway Response to Allergen in Asthmatics (MK-0000-176)
This study will assess the Early Airway Response (EAR) associated change in forced expiratory volume in one second (FEV1) and plasma 9α-11ß-PGF2 ('9P') after single dose pretreatment of nedocromil, montelukast, and mometasone.
- Trial name
- NCT01061333
- Testing
- Nedocromil, Comparator: Montelukast, Comparator: Mometasone
- Volunteers
- 16 people
- Sponsor
- Merck Sharp & Dohme LLC
Bronchiectasis
Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis
The purpose of this study is to find out if bacterial load in the airways can be reduced after inhalation of ciprofloxacin for 28 days.
- Trial name
- NCT00930982
- Testing
- Ciprofloxacin (Cipro, BAYQ3939)
- Where
- 47 sites in United States, Australia and 4 more
- Volunteers
- 124 people
- Sponsor
- Bayer
Nasal Valve Collapse, Nasal Breathing
Latera RCT - Latera vs. Sham Control for Lateral Nasal Valve Collapse
The primary objective of the LATERA RCT is to demonstrate the superiority of the Latera Implant to improve nasal breathing, compared with a Sham Control procedure.
- Trial name
- NCT03400787
- Testing
- Latera Implant
- Where
- 11 sites in United States
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Spirox, Inc.
Asthma
An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation
This is an exploratory study with the following primary objectives: 1) to establish that PET/CT of the lung can reliably distinguish healthy, non-asthmatic participants from participants with severe asthma and an eosinophilic…
- Trial name
- DEAR (NCT02937168)
- Testing
- Reslizumab, Fludeoxyglucose F 18 (FDG)
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Airway Control
Observational Study of Rapid Sequence Intubation Drug Delivery Using Intraosseous and Intravenous Access.
This study will evaluate using intraosseous vascular access and intravenous vascular access to give patients the necessary medications to perform rapid sequence intubation, for patients with airway difficulties.
- Trial name
- NCT01486407
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Vidacare Corporation
Asthma
Effect of Inhaled TD-8236 on Allergen-induced Asthmatic Response
This will be a randomized, double-blind, placebo-controlled study. The study will use a three-period, six-sequence, complete-block, cross-over study design to characterize two doses of inhaled TD-8236 compared to placebo in…
- Trial name
- NCT04150341
- Testing
- TD-8236
- Where
- 2 sites in United Kingdom
- Volunteers
- 24 people
- Sponsor
- Theravance Biopharma
Chronic Obstructive Pulmonary Disease - COPD
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
To assess the bronchodilation of three doses of formoterol fumarate (6 μg, 12 μg and 24 μg) twice daily (BID) administered via Pressair® compared to placebo and to open-label nebulized formoterol fumarate (20 μg and 40 μg).
- Trial name
- NCT02796651
- Testing
- Formoterol fumarate (6 μg), Formoterol furmarate (20 μg), Formoterol fumarate (12 μg)
- Where
- 20 sites in United States
- Volunteers
- 132 people
- Sponsor
- AstraZeneca
Asthma
Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma
Primary Objective: To evaluate the effect of dupilumab, compared to placebo, on airway inflammation in participants with persistent asthma.
- Trial name
- EXPEDITION (NCT02573233)
- Testing
- Dupilumab SAR231893/REGN668, fluticasone propionate and salmeterol, budesonide and formoterol
- Where
- 16 sites in United States, Canada and 4 more
- Volunteers
- 42 people
- Sponsor
- Sanofi
Allergic Asthma
A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma
This was a multicenter, randomized, double-blind, parallel-group, three-arm, placebo-controlled study designed to demonstrate the efficacy of two different formulations of omalizumab compared with placebo in reducing the airway…
- Trial name
- AQUA (NCT00434434)
- Testing
- omalizumab
- Volunteers
- 61 people
- Sponsor
- Genentech, Inc.
Allergic Asthma
Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists
This study aims to investigate the effect of omalizumab on the number of tissue eosinophils and other markers of airway inflammation and remodeling, including thickness of the lamina reticularis, in moderate to severe asthmatics…
- Trial name
- eXplore (NCT00670930)
- Testing
- omalizumab at a dose of 0.016mg/kg/IU/mL
- Where
- 16 sites in United States, Canada and 5 more
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Nasal Alar Collapse, Bilateral
Study of Polyester Implants for the Treatment of External Nasal Valve Collapse (NVC)
The purpose of this study is to research a polyester polyethylene terephthalate (PET) implant for the treatment of external nasal valve collapse (NVC).
- Trial name
- NVC (NCT00729781)
- Testing
- Polyester Implants
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- Medtronic Xomed, Inc.
Asthma, Bronchial Diseases
Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)
A phase 2, multicentre, randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of tezepelumab on airway inflammation in adults with inadequately controlled asthma.
- Conditions
- Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive
- Trial name
- CASCADE (NCT03688074)
- Testing
- Tezepelumab
- Where
- 28 sites in United States, Canada and 3 more
- Volunteers
- 116 people
- Sponsor
- AstraZeneca
Asthma
Repeat Dose Study of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD)
This study is multicenter, double-blinded parallel group design, where participants with moderate to severe asthma with AFAD will be enrolled.
- Trial name
- NCT03393806
- Testing
- GSK3772847
- Where
- 18 sites in France, Netherlands and 2 more
- Volunteers
- 17 people
- Sponsor
- GlaxoSmithKline
Nasal Airway Obstruction
Vivaer® Procedure for Treatment of Nasal Airway Obstruction Study
The purpose of this study is to compare the Vivaer procedure with radiofrequency (RF) energy to sham procedure for treatment of nasal airway obstruction (NAO).
- Trial name
- VATRAC (NCT04549545)
- Testing
- Vivaer ARC Stylus
- Where
- 12 sites in United States
- Volunteers
- 119 people
- Sponsor
- Aerin Medical
Pulmonary Disease, Chronic Obstructive, Lung Diseases
A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease
PF-03635659 is being developed for the treatment of chronic obstructive pulmonary disease. This is a study to examine the safety, pharmacokinetics and pharmacodynamics of PF-03635659 in patients with Chronic Obstructive Pulmonary…
- Conditions
- Pulmonary Disease, Chronic Obstructive, Lung Diseases, Respiratory Tract Diseases, Chronic Obstructive Airway Disease
- Trial name
- NCT01033487
- Testing
- active comparator, Low Dose PF-03635659, Mid Dose PF-03635659
- Where
- Germany
- Volunteers
- 22 people
- Sponsor
- Pfizer